Skip to main content

Table 1 Clinical characteristics between successful and failed PDX engraftment

From: PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications

N = 139 PDX success PDX failure p value
Age(years)
Mean
66.4 ± 6.8 64.8 ± 8.9 0.244*
Gender
 Male 60 (96.8%) 73 (94.8%) 0.692**
 Female 2 (3.2%) 4(5.2%)
Smoking status
 Former or current 61 (98.4%) 76 (98.7%) 1.000**
 Never 1 (1.6%) 1 (1.3%)
Preoperative Chemotherapy
 Yes 3 (4.8%) 13 (16.9%) 0.033**
 No 59 (95.2%) 64 (83.1%)
pTNM stage (7th)
 I 18 (29.0%) 28 (36.4%) 0.348**
 II 29 (46.8%) 25 (32.5%)
 III 14 (22.6%) 23 (29.9%)
 IV 1 (1.6%) 1 (1.3%)
Tumor size
  < 3 cm 13 (21.0%) 25 (32.5%) 0.204**
 3 <  < 5 21 (33.9%) 27 (35.1%)
 5 <  < 7 21 (33.9%) 22 (28.6%)
 7 >  7 (11.3%) 3 (3.9%)
Differentiation
 Well 1 (1.6%) 1 (1.1%) 1.000**
 Moderate 47 (75.8%) 58 (76.3%)
 Poor 14 (22.6%) 17 (22.4%)
Recurrence
 Yes 14 (22.6%) 14 (18.2%) 0.671**
 No 48 (77.4%) 63 (81.8%)
Vascular invasion
 Yes 8 (12.9%) 8 (10.4%) 0.399**
 No 54 (87.1%) 69(92.2%)
Perineural invasion
 Yes 8 (12.9%) 6 (7.8%) 0.399**
 No 54 (87.1%) 71(92.2%)
Lymphatic invasion
 Yes 22 (35.5%) 21 (27.3%) 0.357**
 No 40 (64.5%) 56 (72.7%)
Visceral pleural invasion
 PL0 46 (74.2%) 61 (81.3%) 0.599**
 PL1 1 (1.6%) 2 (2.7%)
 PL2 6 (9.7%) 6 (8.0%)
 PL3 9 (14.5%) 6 (8.0%)
  1. The asterisks (*, **) indicate results from a Mann-Whitney U test and a Fisher’s exact test, respectively